AnDiConBio key facts
- Developer of drugs designed for respiratory anti-infection.
- It has raised $43.4M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Cowin Capital, GSR United Capital, HaiBang Ventures, Heda Ventures, Zhuzhou SAH Innovation & Entrepreneur Investment — 15 tracked in total.
- Status: Privately Held (backing).
Who backs AnDiConBio
15+Membership and data by Private Market View
- ·The complete investor list: 15 names
- ·Watch AnDiConBio: the Monday email on marks, rounds and moves
AnDiConBio funding rounds
No funding rounds for AnDiConBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
AnDiConBio investors
15 investors are on record for AnDiConBio, including Cowin Capital, GSR United Capital, HaiBang Ventures and Heda Ventures.
About AnDiConBio
Developer of drugs designed for respiratory anti-infection. The company has established a product pipeline including a variety of drugs, including new anti-influenza and oral anti-new coronavirus, which have high drug potential and low clinical risks, thereby providing customers with safe and efficient drugs.
- Sector
- Healthcare
- HQ
- Jiaxing, China
- Founded
- 2018
- Employees
- 6
- Website
- andicon.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
AnDiConBio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.